AU2017293271C1 - Imidazo[1,2-α]pyridine derivatives, methods for preparing the same and use thereof - Google Patents

Imidazo[1,2-α]pyridine derivatives, methods for preparing the same and use thereof Download PDF

Info

Publication number
AU2017293271C1
AU2017293271C1 AU2017293271A AU2017293271A AU2017293271C1 AU 2017293271 C1 AU2017293271 C1 AU 2017293271C1 AU 2017293271 A AU2017293271 A AU 2017293271A AU 2017293271 A AU2017293271 A AU 2017293271A AU 2017293271 C1 AU2017293271 C1 AU 2017293271C1
Authority
AU
Australia
Prior art keywords
amino
methanone
pyridin
dimethylimidazo
dimethylbenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017293271A
Other languages
English (en)
Other versions
AU2017293271B2 (en
AU2017293271A1 (en
Inventor
Kwangwoo Chun
Eunsung Jang
Jeongmin Kim
Joseph Kim
Hyunho Lee
Chun-Ho Park
Yoonsun PARK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jeil Pharmaceutical Co Ltd
Original Assignee
Jeil Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeil Pharmaceutical Co Ltd filed Critical Jeil Pharmaceutical Co Ltd
Publication of AU2017293271A1 publication Critical patent/AU2017293271A1/en
Publication of AU2017293271B2 publication Critical patent/AU2017293271B2/en
Application granted granted Critical
Publication of AU2017293271C1 publication Critical patent/AU2017293271C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2017293271A 2016-07-05 2017-07-04 Imidazo[1,2-α]pyridine derivatives, methods for preparing the same and use thereof Active AU2017293271C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160085048A KR101777971B1 (ko) 2016-07-05 2016-07-05 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도
KR10-2016-0085048 2016-07-05
PCT/KR2017/007055 WO2018008929A1 (fr) 2016-07-05 2017-07-04 Dérivés d'imidazo[1,2-a]pyridine, leurs procédés de préparation et leur utilisation

Publications (3)

Publication Number Publication Date
AU2017293271A1 AU2017293271A1 (en) 2019-01-17
AU2017293271B2 AU2017293271B2 (en) 2019-12-05
AU2017293271C1 true AU2017293271C1 (en) 2020-04-23

Family

ID=59926389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017293271A Active AU2017293271C1 (en) 2016-07-05 2017-07-04 Imidazo[1,2-α]pyridine derivatives, methods for preparing the same and use thereof

Country Status (22)

Country Link
US (1) US10696671B2 (fr)
EP (1) EP3481827B1 (fr)
JP (1) JP6713556B2 (fr)
KR (1) KR101777971B1 (fr)
CN (1) CN109415362B (fr)
AU (1) AU2017293271C1 (fr)
CA (1) CA3029745C (fr)
DK (1) DK3481827T3 (fr)
ES (1) ES2900305T3 (fr)
HU (1) HUE057549T2 (fr)
IL (1) IL264075B (fr)
MX (1) MX2018016299A (fr)
MY (1) MY196082A (fr)
NZ (1) NZ749346A (fr)
PH (1) PH12019500015A1 (fr)
PL (1) PL3481827T3 (fr)
PT (1) PT3481827T (fr)
RU (1) RU2725147C1 (fr)
SA (1) SA519400792B1 (fr)
SG (1) SG11201811221XA (fr)
WO (1) WO2018008929A1 (fr)
ZA (1) ZA201900236B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101777971B1 (ko) 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도
KR20190057569A (ko) * 2017-11-20 2019-05-29 제일약품주식회사 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도
WO2020210878A1 (fr) * 2019-04-18 2020-10-22 Borody Thomas J Compositions et méthodes de traitement, d'amélioration et de prévention d'infections par h. pylori
KR102496869B1 (ko) 2022-07-29 2023-02-07 제일약품주식회사 이미다조[1,2-a]피리딘 화합물의 신규 염, 이의 결정형 및 제조방법
WO2024117798A1 (fr) * 2022-11-29 2024-06-06 제일약품 주식회사 Composition destinée à éliminer helicobacter pylori contenant du zastaprazan ou un sel pharmaceutiquement acceptable de celui-ci
KR20240080172A (ko) 2022-11-29 2024-06-05 제일약품주식회사 자스타프라잔 또는 이의 약제학적으로 허용되는 염을 포함하는 헬리코박터 파일로리 제균용 조성물
WO2024117797A1 (fr) * 2022-11-29 2024-06-06 제일약품 주식회사 Composition pharmaceutique pour la prévention ou le traitement d'un ulcère peptique associé à un médicament contenant du zastaprazan ou un sel pharmaceutiquement acceptable de celui-ci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055705A1 (fr) * 1998-04-29 1999-11-04 Astrazeneca Ab Derives d'imidazo pyridine qui inhibent la secretion d'acide gastrique
WO2007039464A1 (fr) * 2005-09-22 2007-04-12 Nycomed Gmbh Dérivés de l'imidazopyridine porteurs de substitutions par des isotopes pour le traitement de troubles gastro-intestinaux

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81219B (en) * 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
GB8722488D0 (en) 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
SE0003186D0 (sv) * 2000-09-07 2000-09-07 Astrazeneca Ab New process
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
PL1784404T3 (pl) 2004-09-03 2012-04-30 Yuhan Corp Pochodne pirolo[2,3-c]pirydyny i sposoby ich wytwarzania
US7498337B2 (en) 2005-08-30 2009-03-03 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
WO2007072146A1 (fr) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazoles substitues par des chromanes et leur utilisation en tant qu’inhibiteurs de la pompe a protons
WO2008015196A1 (fr) 2006-07-31 2008-02-07 Nycomed Gmbh Imidazo[1,2-a]pyridines 5,7-bis-substituées
FI20086158A0 (fi) 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
KR101777971B1 (ko) 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055705A1 (fr) * 1998-04-29 1999-11-04 Astrazeneca Ab Derives d'imidazo pyridine qui inhibent la secretion d'acide gastrique
WO2007039464A1 (fr) * 2005-09-22 2007-04-12 Nycomed Gmbh Dérivés de l'imidazopyridine porteurs de substitutions par des isotopes pour le traitement de troubles gastro-intestinaux

Also Published As

Publication number Publication date
IL264075B (en) 2022-02-01
MX2018016299A (es) 2019-08-29
JP6713556B2 (ja) 2020-06-24
PH12019500015A1 (en) 2019-10-28
WO2018008929A1 (fr) 2018-01-11
EP3481827B1 (fr) 2021-11-03
IL264075A (en) 2019-01-31
CN109415362B (zh) 2021-07-30
EP3481827A1 (fr) 2019-05-15
CA3029745A1 (fr) 2018-01-11
PL3481827T3 (pl) 2022-02-07
CA3029745C (fr) 2020-12-08
ES2900305T3 (es) 2022-03-16
NZ749346A (en) 2020-04-24
AU2017293271B2 (en) 2019-12-05
BR112018077205A2 (pt) 2019-04-09
US20190152971A1 (en) 2019-05-23
MY196082A (en) 2023-03-14
PT3481827T (pt) 2021-12-09
EP3481827A4 (fr) 2019-11-27
HUE057549T2 (hu) 2022-05-28
ZA201900236B (en) 2020-05-27
DK3481827T3 (da) 2021-12-06
AU2017293271A1 (en) 2019-01-17
JP2019524691A (ja) 2019-09-05
US10696671B2 (en) 2020-06-30
SG11201811221XA (en) 2019-01-30
RU2725147C1 (ru) 2020-06-30
CN109415362A (zh) 2019-03-01
SA519400792B1 (ar) 2022-09-01
KR101777971B1 (ko) 2017-09-12

Similar Documents

Publication Publication Date Title
AU2017293271C1 (en) Imidazo[1,2-α]pyridine derivatives, methods for preparing the same and use thereof
KR20200110653A (ko) 섬유모세포 활성화 단백질의 억제제
AU2021293694B2 (en) Novel Acid Secretion Inhibitor and use thereof
TW200920366A (en) 5-membered heterocyclic compound
KR20090106604A (ko) 축합 피리딘 화합물
CN110857293B (zh) 一种新型的喹啉衍生物抑制剂
TW200800185A (en) Acid secretion inhibitor
KR20110071067A (ko) 피롤 화합물
EA023998B1 (ru) Аминохинолины в качестве ингибиторов киназ
KR20110028661A (ko) Ｄｇａｔ１ 억제제로서의 헤테로아릴 유도체
TW202220987A (zh) 經取代雜環化合物及其治療用途
ES2744597T3 (es) Compuestos de heteroarilo con una unidad acíclica como puente
BR112018077205B1 (pt) Derivados de imidazo[1,2-a]piridina, métodos para preparar os mesmos e uso dos mesmos
AU698249B2 (en) Thiopyridines for combating (helicobacter) bacteria
AU2004249655B2 (en) Novel imidazopyridine compound ii with therapeutic effect
KR20190057569A (ko) 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도
KR20160118645A (ko) 1,3,4-싸이아다이아졸-2-아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JAN 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JAN 2020

FGA Letters patent sealed or granted (standard patent)